Name: OMEROS CORP (OMER) Stock
Brand: OMEROS CORP
Rating: 9 (3 reviews)

OMER Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Chartmill - Mentions: REE GNPX GWH SGBX ...

In today's session, these stocks are experiencing unusual volume.

14 days ago - By: Chartmill - Mentions: NVX SMSI ADTX BLBX ...

In today's session, these stocks are experiencing unusual volume.

9 days ago - By: Benzinga - Mentions: ACHV RANI ARTV

4 Biotech Stocks Lifting Off As Momentum Builds

13 days ago - By: Benzinga - Mentions: SLI SLB WTO RANI ...

Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings

14 days ago - By: Omeros Corporation

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

15 days ago - By: The Motley Fool - Mentions: NVO

A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?

15 days ago - By: Stocktwits - Mentions: NVO

Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside

15 days ago - By: Investor's Business Daily - Mentions: AKRO

Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk

15 days ago - By: Chartmill - Mentions: SEED FOSL AWX SIFY ...

Here are the top movers in Wednesday's session.

15 days ago - By: Chartmill - Mentions: SEED AWX PXLW TRUE ...

Gapping stocks in Wednesday's session

15 days ago - By: Stocktwits - Mentions: NVO

Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder

2 months ago - By: Omeros Corporation

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

3 months ago - By: The Motley Fool

Omeros Posts 2,652 Percent Sales Jump

3 months ago - By: Omeros Corporation

Omeros Corporation Reports Second Quarter 2025 Financial Results

3 months ago - By: Omeros Corporation

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

3 months ago - By: ACCESS Newswire

D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering

3 months ago - By: Omeros Corporation

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

4 months ago - By: Stocktwits

Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost

4 months ago - By: Omeros Corporation

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

4 months ago - By: Omeros Corporation

OMEROS CORP (OMER) Stock News

OMER Latest News, Press Relases and Analysis

In today's session, these stocks are experiencing unusual volume.

In today's session, these stocks are experiencing unusual volume.

4 Biotech Stocks Lifting Off As Momentum Builds

Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?

Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside

Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk

Here are the top movers in Wednesday's session.

Gapping stocks in Wednesday's session

Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Omeros Posts 2,652 Percent Sales Jump

Omeros Corporation Reports Second Quarter 2025 Financial Results

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Omeros Announces Webcast Details for Annual Meeting of Shareholders